Aura Biosciences, Inc. Financials
This page shows Aura Biosciences, Inc. (AURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aura’s economics are defined by equity-funded R&D spending: losses consume cash directly while the balance sheet stays lightly leveraged.
From FY2024 to FY2025, operating cash burn worsened from$79.8M to$84.7M as the research program expanded. Yet cash rose from$31.7M to$59.5M because financing supplied new capital, meaning the stronger year-end cash position came from shareholders rather than from a cheaper operating model.
Earnings quality is straightforward: FY2025 net loss of
The spending mix is becoming more research-heavy: R&D reached
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Aura Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aura Biosciences, Inc. carries a low D/E ratio of 0.24, meaning only $0.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.15, Aura Biosciences, Inc. holds $8.15 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Aura Biosciences, Inc. generates a -77.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -57.2% the prior year.
Aura Biosciences, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Aura Biosciences, Inc. generates $0.80 in operating cash flow (-$84.7M OCF vs -$106.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Aura Biosciences, Inc.'s EBITDA was -$111.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.7% from the prior year.
Aura Biosciences, Inc. reported -$106.2M in net income in fiscal year 2025. This represents a decrease of 22.2% from the prior year.
Aura Biosciences, Inc. earned $-1.76 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 0.6% from the prior year.
Cash & Balance Sheet
Aura Biosciences, Inc. generated -$85.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 5.1% from the prior year.
Aura Biosciences, Inc. held $59.5M in cash against $0 in long-term debt as of fiscal year 2025.
Aura Biosciences, Inc. had 64M shares outstanding in fiscal year 2025. This represents an increase of 27.2% from the prior year.
Margins & Returns
Aura Biosciences, Inc.'s ROE was -77.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.4 percentage points from the prior year.
Capital Allocation
Aura Biosciences, Inc. invested $90.3M in research and development in fiscal year 2025. This represents an increase of 23.2% from the prior year.
Aura Biosciences, Inc. invested $447K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 64.3% from the prior year.
AURA Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $28.0M | N/A | $22.2M-3.1% | $22.9M-2.0% | $23.3M | N/A | $17.0M+0.9% | $16.9M |
| SG&A Expenses | $6.9M | N/A | $5.7M-0.1% | $5.7M+0.7% | $5.7M | N/A | $6.2M+5.3% | $5.9M |
| Operating Income | -$34.9M | N/A | -$27.9M+2.5% | -$28.6M+1.5% | -$29.0M | N/A | -$23.2M-2.1% | -$22.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $11K | N/A | $26K-45.8% | $48K+166.7% | $18K | N/A | $43K | N/A |
| Net Income | -$33.7M | N/A | -$26.1M+3.3% | -$27.0M+1.7% | -$27.5M | N/A | -$21.0M-3.5% | -$20.3M |
| EPS (Diluted) | $-0.50 | N/A | $-0.40+14.9% | $-0.47+14.5% | $-0.55 | N/A | $-0.42-2.4% | $-0.41 |
AURA Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $137.7M-18.7% | $169.4M-10.8% | $190.0M-7.0% | $204.4M+31.5% | $155.4M-14.9% | $182.5M-11.1% | $205.3M-5.9% | $218.3M |
| Current Assets | $118.5M-20.9% | $149.7M-12.0% | $170.1M-7.5% | $184.0M+36.8% | $134.5M-16.3% | $160.6M-12.5% | $183.5M-6.2% | $195.6M |
| Cash & Equivalents | $84.8M+42.5% | $59.5M+25.2% | $47.6M-55.7% | $107.4M+180.9% | $38.2M+20.6% | $31.7M+24.7% | $25.4M-15.5% | $30.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $30.4M-6.4% | $32.5M-2.5% | $33.4M+12.1% | $29.8M+8.5% | $27.4M-10.1% | $30.5M-0.5% | $30.7M+14.3% | $26.8M |
| Current Liabilities | $16.7M-9.1% | $18.4M-2.3% | $18.8M+26.7% | $14.9M+22.1% | $12.2M-18.4% | $14.9M+1.4% | $14.7M+39.5% | $10.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $107.2M-21.7% | $136.9M-12.6% | $156.7M-10.3% | $174.6M+36.5% | $128.0M-15.8% | $152.0M-13.0% | $174.7M-8.8% | $191.5M |
| Retained Earnings | -$514.1M-7.0% | -$480.4M-5.6% | -$454.9M-6.1% | -$428.7M-6.7% | -$401.7M-7.3% | -$374.2M-7.4% | -$348.4M-6.4% | -$327.4M |
AURA Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.9M-46.0% | -$20.5M-1.6% | -$20.1M+3.0% | -$20.8M+11.1% | -$23.4M+2.5% | -$24.0M-56.8% | -$15.3M+5.3% | -$16.1M |
| Capital Expenditures | $102K-42.0% | $176K+291.1% | $45K+15.4% | $39K-79.1% | $187K-37.5% | $299K-12.3% | $341K-35.0% | $525K |
| Free Cash Flow | -$30.0M-45.3% | -$20.6M-2.3% | -$20.2M+3.0% | -$20.8M+11.6% | -$23.5M+2.9% | -$24.3M-55.3% | -$15.6M+6.2% | -$16.7M |
| Investing Cash Flow | $54.9M+84.1% | $29.8M+167.8% | -$44.0M-320.3% | $20.0M-33.0% | $29.8M+0.4% | $29.7M+200.3% | $9.9M-50.2% | $19.8M |
| Financing Cash Flow | $300K-89.2% | $2.8M-36.6% | $4.4M-93.8% | $69.9M+72742.7% | $96K-82.3% | $543K-24.2% | $716K+762.7% | $83K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AURA Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -31.4% | N/A | -16.7%-1.2pp | -15.5%+6.0pp | -21.5% | N/A | -12.0%-1.4pp | -10.6% |
| Return on Assets | -24.5% | N/A | -13.8%-0.5pp | -13.2%+4.5pp | -17.7% | N/A | -10.3%-0.9pp | -9.3% |
| Current Ratio | 7.09-1.1 | 8.15-0.9 | 9.04-3.3 | 12.39+1.3 | 11.06+0.3 | 10.77-1.7 | 12.47-6.1 | 18.54 |
| Debt-to-Equity | 0.28+0.0 | 0.24+0.0 | 0.21+0.0 | 0.17-0.0 | 0.21+0.0 | 0.20+0.0 | 0.18+0.0 | 0.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Aura Biosciences, Inc. profitable?
No, Aura Biosciences, Inc. (AURA) reported a net income of -$106.2M in fiscal year 2025.
What is Aura Biosciences, Inc.'s EBITDA?
Aura Biosciences, Inc. (AURA) had EBITDA of -$111.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aura Biosciences, Inc.'s return on equity (ROE)?
Aura Biosciences, Inc. (AURA) has a return on equity of -77.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aura Biosciences, Inc.'s free cash flow?
Aura Biosciences, Inc. (AURA) generated -$85.2M in free cash flow during fiscal year 2025. This represents a -5.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aura Biosciences, Inc.'s operating cash flow?
Aura Biosciences, Inc. (AURA) generated -$84.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aura Biosciences, Inc.'s total assets?
Aura Biosciences, Inc. (AURA) had $169.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aura Biosciences, Inc.'s capital expenditures?
Aura Biosciences, Inc. (AURA) invested $447K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aura Biosciences, Inc. spend on research and development?
Aura Biosciences, Inc. (AURA) invested $90.3M in research and development during fiscal year 2025.
What is Aura Biosciences, Inc.'s current ratio?
Aura Biosciences, Inc. (AURA) had a current ratio of 8.15 as of fiscal year 2025, which is generally considered healthy.
What is Aura Biosciences, Inc.'s debt-to-equity ratio?
Aura Biosciences, Inc. (AURA) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aura Biosciences, Inc.'s return on assets (ROA)?
Aura Biosciences, Inc. (AURA) had a return on assets of -62.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aura Biosciences, Inc.'s cash runway?
Based on fiscal year 2025 data, Aura Biosciences, Inc. (AURA) had $59.5M in cash against an annual operating cash burn of $84.7M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Aura Biosciences, Inc.'s Piotroski F-Score?
Aura Biosciences, Inc. (AURA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aura Biosciences, Inc.'s earnings high quality?
Aura Biosciences, Inc. (AURA) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Aura Biosciences, Inc.?
Aura Biosciences, Inc. (AURA) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.